AstraZeneca plc (AZN) Given a GBX 4,500 Price Target at J P Morgan Chase & Co
J P Morgan Chase & Co set a GBX 4,500 ($59.79) target price on AstraZeneca plc (LON:AZN) in a research report released on Wednesday. The firm currently has a neutral rating on the biopharmaceutical company’s stock.
AZN has been the topic of several other reports. HSBC Holdings plc reiterated a reduce rating and issued a GBX 4,100 ($54.48) price target on shares of AstraZeneca plc in a research note on Monday, September 11th. Barclays PLC reiterated an overweight rating and issued a GBX 6,300 ($83.71) price target on shares of AstraZeneca plc in a research note on Thursday, October 5th. UBS AG set a GBX 5,150 ($68.43) price target on shares of AstraZeneca plc and gave the company a neutral rating in a research note on Tuesday, June 27th. BNP Paribas set a GBX 5,300 ($70.42) price target on shares of AstraZeneca plc and gave the company a neutral rating in a research note on Monday, September 11th. Finally, Citigroup Inc. reiterated a buy rating and issued a GBX 6,000 ($79.72) price target on shares of AstraZeneca plc in a research note on Friday, July 28th. Three equities research analysts have rated the stock with a sell rating, seven have issued a hold rating and twelve have issued a buy rating to the stock. The company currently has a consensus rating of Hold and an average target price of GBX 5,172.64 ($68.73).
Shares of AstraZeneca plc (AZN) traded down 0.02% during midday trading on Wednesday, reaching GBX 5175.00. 2,555,117 shares of the company were exchanged. The company’s market capitalization is GBX 65.52 billion. The stock has a 50-day moving average price of GBX 4,904.35 and a 200 day moving average price of GBX 4,912.64. AstraZeneca plc has a 52-week low of GBX 3,996.00 and a 52-week high of GBX 5,520.00.
In other news, insider Nazneen Rahman bought 39 shares of the company’s stock in a transaction dated Thursday, July 27th. The stock was bought at an average cost of GBX 4,370 ($58.07) per share, for a total transaction of £1,704.30 ($2,264.55).
About AstraZeneca plc
AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on discovery and development of products, which are then manufactured, marketed and sold. The Company focuses on three main therapy areas: Oncology, Cardiovascular & Metabolic Disease (CVMD) and Respiratory, while selectively pursuing therapies in Autoimmunity, Infection and Neuroscience.
Receive News & Ratings for AstraZeneca plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca plc and related companies with Analyst Ratings Network's FREE daily email newsletter.